Potential Breakthrough in Alzheimer’s Research

A study from Baylor College of Medicine in the US might lead to new therapies aimed at eliminating the annoying protein clumps linked to Alzheimer’s disease.

By using specially bred mice that mimic some symptoms of this neurodegenerative disorder, researchers discovered that higher levels of a protein known as Sox9 prompted certain brain cells to work overtime, effectively “vacuuming” up these plaques more efficiently.

Interestingly, the mice that received this treatment displayed improved performance in tests focused on memory and behavior. This suggests that the approach may not only help protect the brain but could potentially reverse some cognitive decline, a hallmark of Alzheimer’s as neuron damage occurs.

The team identified that the advantages associated with Sox9 came from its ability to enhance the expression of a receptor called MEGF10. This receptor is found exclusively on the membranes of astrocytes, the brain’s maintenance cells tasked with clearing away amyloid-beta plaques.

“Astrocytes play many vital roles in maintaining brain function, including aiding communication and memory storage,” notes Dong-Joo Choi, a neuroscientist formerly at Baylor and now at the University of Texas Health Science Center at Houston.

He adds, “As the brain ages, astrocytes undergo significant changes in function, but we are still trying to grasp what these changes mean for aging and neurodegeneration.”

The researchers discovered that increasing Sox9 levels seemed to revitalize aging astrocytes. Interestingly, Sox9 has already been observed at higher levels in Alzheimer’s-affected brains, which might indicate the brain’s effort to enhance waste removal.

In another part of the study, the team experimented by genetically engineering mice to lack Sox9. The results showed that these mice’s astrocytes exhibited poorer health, memory recall was diminished, and they accumulated more amyloid-beta clumps.

Choi elaborates, “An essential aspect of our experiment was that we used mouse models that already exhibited cognitive impairment and had amyloid plaques. We believe this choice makes our models more relevant to many Alzheimer’s patients than others that study conditions before plaque formation.”

Researchers are pursuing a variety of strategies against Alzheimer’s, including approaches targeting amyloid-beta plaques. However, not all treatments yield success, highlighting the complexity of the disease.

While there are numerous ways to clear or prevent amyloid-beta clumps from forming, it remains unclear whether these aggregates cause Alzheimer’s or simply arise due to the disease. This dilemma is something researchers need to consider going forward.

Each new study brings us a step closer to understanding the progression of Alzheimer’s and, hopefully, how to halt it. Although these recent tests were conducted on mice rather than humans, there’s optimism that a vital new path to managing Alzheimer’s symptoms has been uncovered.

Choi notes, “Most current therapies target neurons or work to inhibit plaque formation. This study indicates that enhancing the natural cleanup capabilities of astrocytes could be equally essential.”

This research has been published in Nature Neuroscience.